Confined or spread disease-Spread to regional lymph nodes - Page 2 of 13 Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread to regional lymph nodes Posts on Medivizor

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Posted by on Dec 26, 2020 in Breast cancer | 0 comments

In a nutshell The study compared outcomes of utidelone plus capecitabine (Xeloda) versus capecitabine (C) alone in previously treated patients with anthracycline- and taxane-resistant metastatic breast cancer (MBC). The authors found that this combination improved survival compared to C alone in such patients. Some background...

Read More

Searching for patients with metastatic breast cancer to trial a targeted therapy

Searching for patients with metastatic breast cancer to trial a targeted therapy

Posted by on Dec 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...

Read More

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Posted by on Oct 23, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...

Read More

An examination of pertuzumab and trastuzumab as breast cancer treatment before surgery in a real-life setting

An examination of pertuzumab and trastuzumab as breast cancer treatment before surgery in a real-life setting

Posted by on Sep 26, 2020 in Breast cancer | 0 comments

In a nutshell This study examined the effectiveness and safety of the drug combination pertuzumab (Perjeta) and trastuzumab (Herceptin) as a treatment for breast cancer (BC) with positive HER2 (human epidermal growth factor receptor 2) before surgery to remove the tumor in a real-world setting. The data showed that this...

Read More

Can a combination of dabrafenib and trametinib improve relapse-free survival after removal of stage 3 melanoma?

Can a combination of dabrafenib and trametinib improve relapse-free survival after removal of stage 3 melanoma?

Posted by on Sep 24, 2020 in Melanoma | 0 comments

In a nutshell This study investigated the long-term effectiveness and risks of the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with stage 3 melanoma after tumor removal. It showed that the combination of the two drugs can increase survival without return or spreading of cancer. Some...

Read More

Looking for patients with advanced breast cancer to trial an experimental drug treatment.

Looking for patients with advanced breast cancer to trial an experimental drug treatment.

Posted by on Sep 20, 2020 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...

Read More

The effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment

The effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment

Posted by on Jul 5, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the link between statin (cholesterol-lowering drugs) use and risks of breast cancer (BC) relapse under adjuvant aromatase inhibitors (AI) therapy in women after their menopause. The main finding was that statin use was related with lower risks of BC relapse in such patients. Some background Women with...

Read More

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...

Read More

How common are allergic reactions to different biological therapies in patients with advanced melanoma?

How common are allergic reactions to different biological therapies in patients with advanced melanoma?

Posted by on May 16, 2020 in Melanoma | 0 comments

In a nutshell This study compared the frequency of allergic reactions to different doses of three biological therapies in patients with advanced melanoma. The authors found that different doses of the three drugs reduced the number of allergic reactions. Some background Biological therapy has significantly improved treatment results for patients...

Read More